|
17-013-6
|
|
Retrospective study to investigate clinical utility of BIOARRAY Therapeutics genomic panel as a predictor of pathological response in breast cancer patients treated with taxane-based neoadjuvant chemotherapy as well as in patients who have developed metastatic disease.
|
|
Dr. Susan Tannenbaum
|
|
In our study we are partnering with BIOARRAY Therapeutics. It is a biotechnology company that has developed a genomic profiling test based algorithm. This algorithm can predict response in breast cancer patients when treated with taxane-based chemotherapy. This information can help physicians personalize treatments upfront. The goal of this study is to validate using retrospective samples, the ability to predict response based on their BIOARRAY test profile.
|
Cancer - Breast
|
|
|
Check with study contact
|
|
Quratulain Ali. Telephone: 860-679-7648. Email: Qali@uchc.edu
|
|
Enrolling/recruiting. For current recruitment status, please check with study contact.
|